Agios Pharmaceuticals Inc. (AGIO)
Symbol Info
Listed Symbol AGIO
Name Agios Pharmaceuticals Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $94,387,000
Latest Fiscal EPS $-6.03
Price Info
21 Day Moving Average $37.1443
21 Day EMA $37.699840
50 Day Moving Average $41.4356
50 Day EMA $40.828490
200 Day EMA $51.559610
200 Day Moving Average 51.437700
52 Week High $79.17
52 Week Low $33.17
52 Week Change $-50.912500
Alpha -0.012552
Beta 2.3209
Standard Deviation 0.167508
R2 0.227596
Periods 60
Share Information
10 Day Average Volume 634,095
20 Day Average Volume 575,172
30 Day Average Volume 557,338
50 Day Average Volume 567,211
Outstanding Shares 58,752,886
Float Shares 57,954,813
Percent Float 98.64%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 458
Institute Holdings Date 2019-08-31
Institute Bought Previous 3 Months 6,212,513
Institute Holdings Percent -
Institute Sold Previous 3 Months 5,942,400
Insider Holdings Date
Insider Bought Previous 3 Months -
Insider Holdings Percent -
Insider Sold Previous 3 Months -
Insiders Shares Owned 798,073
Price Change
7 Day Price Change $-1.4300003
7 Day Percent Change -3.79%
21 Day Price Change $-1.6399994
21 Day Percent Change -4.32%
30 Day Price Change $-6.6800003
30 Day Percent Change -15.54%
Month To Date Price Change $-1.64
Month To Date Percent -4.32%
90 Day Price Change $-14.989998
90 Day Percent Change -29.22%
Quarter To Date $-13.57
Quarter To Date Percent -27.21%
180 Day Price Change $-27.95
180 Day Percent Change -43.50%
200 Day Price Change $-31.189999
200 Day Percent Change -46.21%
Year To Date $-9.799999
Year To Date Percent -21.25%
Profile
Description Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
Details
Issue Type CS
Market Cap $2,133,317,291
Sec Type EQS
Auditor PricewaterhouseCoopers LLP
Total Shares Outstanding 58,752,886
CEO Jacqualyn A. Fouse
Employees 482
Last Audit UE
Classification
CIK 0001439222
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 88 Sidney Street
Cambridge, MA 2139
Website http://www.agios.com
Facisimile +1 302 655-5049
Telephone +1 617 649-8600
Email Renee.Leck@agios.com
Key Ratios
Profitability
EBIT Margin -400.2
EBITDA Margin -392.6
Pre-Tax Profit Margin -332.8
Profit Margin Cont -
Gross Margin 98.00
Profit Margin TOT -
Income Statements
Revenue $101,659,000
Revenue Per Share $1.7303
Revenue 3 Years $18.35
Revenue 5 Years $12.61
Valuation Measures
PE Ratio -
Enterprise Value $1,765,560,339
Price To Sales 20.985033
Price To Free Cash -6.5
PE High Last 5 Years -
Price To Book 3.7
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book 4.1
Financial Strength
Total Debt To Equity 0.2
Int Coverage -
Current Ratio 6.0
Leverage Ratio 1.3
Quick Ratio 5.7
Long Term Debt To Capital 0.17
Assets
Receivables Turnover 4.1
Invoice Turnover 0.90
Assets Turnover -
Management Effectiveness
Return Assets -43.7
Return On Equity -57.44
Return On Capital -51.22
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
AGIO
Agios Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.